SCHEMBL7913301

SCHEMBL7913301

COC(=O)c1cc2c(nc1Cl)CCCCC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.49
SMN1; SMN2 Q16637 8/20 0.48
ALDH1A1 P00352 8/20 0.48
MAPT P10636 4/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
ACHE P22303 4/20 0.46
SLC9A1 P19634 1/20 0.46
KMT2A Q03164 2/20 0.44
GRM1 Q13255 2/20 0.44
PPARG P37231 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
LMNA P02545 4/20 0.42
MAPK1 P28482 2/20 0.42
HSP90AA1 P07900 1/20 0.42
TP53 P04637 2/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30681912 1.00 KDM4E (0.49) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL26618036 1.00 KDM4E (0.49) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL9871030 0.98 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL24517228 0.95 KDM4E (0.47) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL29378235 0.95 KDM4E (0.47) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL2897233 0.85 KDM4E (0.70) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL927885 0.84 SLC9A1 (0.60) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL31345629 0.84 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL26617630 0.84 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A
SCHEMBL26617915 0.84 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514789-A1 <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN SiteOne Therapeutics, Inc. (US) 2025-03-05 EP disclosed
WO-2023211990-A1 BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed
WO-2023211990-A1 BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed
US-11066357-B2 Benzoannulene derivatives as antiviral agents SOUTHERN RESEARCH INSTITUTE (US) 2021-07-20 US disclosed
US-11066357-B2 Benzoannulene derivatives as antiviral agents SOUTHERN RESEARCH INSTITUTE (US) 2021-07-20 US disclosed
US-20210078937-A1 BENZOANNULENE DERIVATIVES AS ANTIVIRAL AGENTS SOUTHERN RESEARCH INSTITUTE 2021-03-18 US disclosed
US-20210078937-A1 BENZOANNULENE DERIVATIVES AS ANTIVIRAL AGENTS SOUTHERN RESEARCH INSTITUTE 2021-03-18 US disclosed
US-6258829-B1 ANTIARRTHMIA AGENTS AND CARDIOVASCULAR DISORDERS TOA EIYO LTD. (JP) 2001-07-10 US disclosed
EP-0972767-A1 CYCLOALKA[b]PYRIDINE-3-CARBONYLGUANIDINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND DRUGS CONTAINING THE SAME TOA EIYO LTD. (JP) 2000-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078937-A1 BENZOANNULENE DERIVATIVES AS ANTIVIRAL AGENTS ZC3HAV1, MAVS, ZC3HAV1L KDM4E 1009/4885SMN1; SMN2 1489/4885ALDH1A1 844/4885
US-11066357-B2 Benzoannulene derivatives as antiviral agents ZC3HAV1, MAVS, ZC3HAV1L KDM4E 1009/4885SMN1; SMN2 1489/4885ALDH1A1 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.